Q-omics provides the consensus-scored RTP5 profile across patient tissues and cancer cell-line models. RTP5 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, RTP5 is differentially expressed in 7, with the highest sampling consensus in LUSC. Additionally, RTP5 RNA expression shows 14,539 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight SKCM, LUSC, and LSCC as cancer lineages where RTP5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RTP5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RTP5 survival associations across molecular data types. RTP5 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RTP5 RNA expression–survival associations across cancer types. High RTP5 expression shows unfavorable associations in KIRC and UVM, but favorable associations in SKCM, LIHC, LGG and HNSC. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for RTP5 RNA expression.
This table summarizes RTP5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for RTP5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RTP5 shows lower tumor expression in LUSC, THCA, BRCA, KICH and LUAD and higher tumor expression in KIRC. The LUSC box plot shows higher RTP5 RNA expression in normal versus tumor tissue (log2 FC = −0.251, t-test p < 0.001).
This table shows molecular features associated with RTP5 in patient tissues and cancer cell lines. In patient samples, RTP5 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, RTP5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BLOOD_Leukemia.
